Literature DB >> 29739787

Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms.

Ivana Peran1, Subha Madhavan2,3, Stephen W Byers2, Matthew D McCoy1,3.   

Abstract

Purpose: Publicly available databases, for example, The Cancer Genome Atlas (TCGA), containing clinical and molecular data from many patients are useful in validating the contribution of particular genes to disease mechanisms and in forming novel hypotheses relating to clinical outcomes.Experimental Design: The impact of key drivers of cancer progression can be assessed by segregating a patient cohort by certain molecular features and constructing survival plots using the associated clinical data. However, conclusions drawn from this straightforward analysis are highly dependent on the quality and source of tissue samples, as demonstrated through the pancreatic ductal adenocarcinoma (PDAC) subset of TCGA.
Results: Analyses of the PDAC-TCGA database, which contains mainly resectable cancer samples from patients in stage IIB, reveal a difference from widely known historic median and 5-year survival rates of PDAC. A similar discrepancy was observed in lung, stomach, and liver cancer subsets of TCGA. The whole transcriptome expression patterns of PDAC-TCGA revealed a cluster of samples derived from neuroendocrine tumors, which have a distinctive biology and better disease prognosis than PDAC. Furthermore, PDAC-TCGA contains numerous pseudo-normal samples, as well as those that arose from tumors not classified as PDAC.Conclusions: Inclusion of misclassified samples in the bioinformatic analyses distorts the association of molecular biomarkers with clinical outcomes, altering multiple published conclusions used to support and motivate experimental research. Hence, the stringent scrutiny of type and origin of samples included in the bioinformatic analyses by researchers, databases, and web-tool developers is of crucial importance for generating accurate conclusions. Clin Cancer Res; 24(16); 3813-9. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29739787     DOI: 10.1158/1078-0432.CCR-18-0290

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

1.  Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.

Authors:  Christian K Hirt; Tijmen H Booij; Linda Grob; Patrik Simmler; Nora C Toussaint; David Keller; Doreen Taube; Vanessa Ludwig; Alexander Goryachkin; Chantal Pauli; Daniela Lenggenhager; Daniel J Stekhoven; Christian U Stirnimann; Katharina Endhardt; Femke Ringnalda; Lukas Villiger; Alexander Siebenhüner; Sofia Karkampouna; Marta De Menna; Janette Beshay; Hagen Klett; Marianna Kruithof-de Julio; Julia Schüler; Gerald Schwank
Journal:  Cell Genom       Date:  2022-02

2.  Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses.

Authors:  Archana Bhardwaj; Claire Josse; Daniel Van Daele; Christophe Poulet; Marcela Chavez; Ingrid Struman; Kristel Van Steen
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

3.  TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment.

Authors:  Martino Maddalena; Giuseppe Mallel; Nishanth Belugali Nataraj; Michal Shreberk-Shaked; Ori Hassin; Saptaparna Mukherjee; Sharathchandra Arandkar; Ron Rotkopf; Abby Kapsack; Giuseppina Lambiase; Bianca Pellegrino; Eyal Ben-Isaac; Ofra Golani; Yoseph Addadi; Emma Hajaj; Raya Eilam; Ravid Straussman; Yosef Yarden; Michal Lotem; Moshe Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

4.  Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.

Authors:  Concetta Panebianco; Nadia Trivieri; Annacandida Villani; Fulvia Terracciano; Tiziana Pia Latiano; Adele Potenza; Francesco Perri; Elena Binda; Valerio Pazienza
Journal:  Biomolecules       Date:  2021-04-26

5.  Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.

Authors:  Felix Orben; Katharina Lankes; Christian Schneeweis; Zonera Hassan; Hannah Jakubowsky; Lukas Krauß; Fabio Boniolo; Carolin Schneider; Arlett Schäfer; Janine Murr; Christoph Schlag; Bo Kong; Rupert Öllinger; Chengdong Wang; Georg Beyer; Ujjwal M Mahajan; Yonggan Xue; Julia Mayerle; Roland M Schmid; Bernhard Kuster; Roland Rad; Christian J Braun; Matthias Wirth; Maximilian Reichert; Dieter Saur; Günter Schneider
Journal:  JCI Insight       Date:  2022-05-23

6.  EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer.

Authors:  Hwa-Ryeon Kim; Juhye Yim; Hye-Been Yoo; Seung Eon Lee; Sumin Oh; Sungju Jung; Chang-Il Hwang; Dong-Myung Shin; TaeSoo Kim; Kyung Hyun Yoo; You-Sun Kim; Han-Woong Lee; Jae-Seok Roe
Journal:  NAR Cancer       Date:  2021-06-17

7.  Gα15 in early onset of pancreatic ductal adenocarcinoma.

Authors:  Giulio Innamorati; Thomas M Wilkie; Giorgio Malpeli; Salvatore Paiella; Silvia Grasso; Borislav Rusev; Biagio Eugenio Leone; Maria Teresa Valenti; Luca Dalle Carbonare; Samuele Cheri; Alice Giacomazzi; Marco Zanotto; Vanessa Guardini; Michela Deiana; Donato Zipeto; Michela Serena; Marco Parenti; Francesca Guzzi; Rita Teresa Lawlor; Giovanni Malerba; Antonio Mori; Giuseppe Malleo; Luca Giacomello; Roberto Salvia; Claudio Bassi
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

8.  Genomewide identification of a novel six-LncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma.

Authors:  Ying Wu; Peng-Shuo Wang; Ben-Gang Wang; Lu Xu; Wan-Xia Fang; Xiao-Fang Che; Xiu-Juan Qu; Yun-Peng Liu; Zhi Li
Journal:  Cancer Med       Date:  2018-10-30       Impact factor: 4.452

9.  Computational STAT3 activity inference reveals its roles in the pancreatic tumor microenvironment.

Authors:  Evelien Schaafsma; Yiwei Yuan; Yanding Zhao; Chao Cheng
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

10.  Autophagy Regulatory Genes MET and RIPK2 Play a Prognostic Role in Pancreatic Ductal Adenocarcinoma: A Bioinformatic Analysis Based on GEO and TCGA.

Authors:  Xingyu Li; Zhiqiang Li; Hongwei Zhu; Xiao Yu
Journal:  Biomed Res Int       Date:  2020-11-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.